A Faster Route to Antibody Peptide Maps - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Faster Route to Antibody Peptide Maps

  • November 18, 2026

  • 3 min

Share

Objective:

The article examines the objective, findings, and clinical context described in A Faster Route to Antibody Peptide Maps.

Approach:
  • Workflow: The method replaces liquid chromatography with automated nanoelectrospray infusion, combining 96-well sample preparation, high-resolution Orbitrap mass spectrometry, and software for peptide matching and modification analysis.
  • Sample preparation and throughput: Antibodies undergo reduction, alkylation, precipitation, washing, and tryptic digestion in a filter plate. Preparation takes about four hours; analysis takes about 60 seconds per sample, with roughly two minutes per sample-to-sample cycle.
  • Evaluation: Researchers assessed sequence coverage, modification detection, sensitivity, and performance in forced-degradation studies, including a 1,152-sample demonstration.
Key Findings:
  • Across more than 1,500 experiments involving 28 antibody sequences, median sequence coverage was 100% and mean coverage was 97.7%.
  • The workflow detected oxidation, deamidation, glycosylation, terminal modifications, sequence variants, and antibody-drug conjugation sites.
  • Oxidation measurements in forced-degradation studies correlated closely with conventional LC-MS results.
  • Stable isotope-labeled peptides showed an average detection limit of about 0.7% relative abundance, varying from 0.2% to 1.2% by peptide.
  • The team analyzed 1,152 forced-degradation samples in about 35.5 hours.
Interpretation:

The authors position RaPiD-mAb-MS for discovery, formulation screening, and process development. They note that conventional LC-MS remains important for ultratrace detection and established regulated quality-control workflows.

Limitations:
  • Sensitivity is lower than targeted LC-MS/MS can achieve for some low-abundance species.
  • Deamidated and unmodified peptides can overlap, requiring high-resolution targeted MS/MS.
  • Isoaspartate cannot be detected directly because it is isobaric with aspartate; an optional enzymatic labeling step creates a measurable mass shift.
  • Further method-specific qualification would be needed before direct infusion could support regulated testing.
Conclusion:

The workflow can process 96 samples in approximately 1.5 to two hours of analysis, in addition to about four hours of sample preparation.

Original Source(s)

Related Content